Galecto
Focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 -12.2x EV/EBITDA | round | |
| N/A | $85.0m Valuation: $369m -11.4x EV/EBITDA | IPO | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Galecto, Inc. is a biotechnology company specializing in the development of innovative treatments for fibrosis and cancer. The company focuses on creating small molecule inhibitors targeting galectin-3 and LOXL2, which are proteins implicated in various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and certain cancers. Galecto operates in the pharmaceutical and biotechnology market, primarily serving patients suffering from fibrotic conditions and cancer. The company's business model revolves around research and development (R&D) of novel therapeutics, progressing through clinical trials, and eventually partnering with larger pharmaceutical companies or bringing their products to market independently. Revenue is generated through licensing agreements, partnerships, and potential future sales of approved drugs.
Keywords: biotechnology, fibrosis, cancer, galectin-3, LOXL2, small molecules, clinical trials, pharmaceuticals, therapeutics, R&D.